Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The increasing mastery over the virus is one of humanity’s crowning achievements.
Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
A decade of aging brings on heart and kidney troubles in people with HIV.
A study finds that CD4 cells decline after people with HIV contract hepatitis C.
Treatment efficacy has steadily improved since effective combination HIV therapy first entered advanced clinical trials in the mid-1990s.
A look at 2009 to 2014 data found that those in care for HIV saw a considerable fall in treatment deferrals.
For over 30 years, the California-based group fought for treatments, research, education and quality health care.
Fostemsavir offers HIV treatment hope to those with no other options.
Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
December 2018 Survey
NMAC offers support and engagement opportunities to advocates living with HIV who are 50 and over.
Aprende más sobre la prevención y el tratamiento del VIH para mantenerse saludable.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.